Mr Richard Perry. Colorectal Surgeon Christchurch

Similar documents
Serrated Polyps and a Classification of Colorectal Cancer

Colorectal Cancer Screening and Surveillance

Mr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer

Colorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi

Development of Carcinoma Pathways

Screening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee

Colon Cancer and Hereditary Cancer Syndromes

The silence of the genes: clinical applications of (colorectal) cancer epigenetics

CRC Risk Factors. U.S. Adherence Rates Cancer Screening. Genetic Model of Colorectal Cancer. Epidemiology and Clinical Consequences of CRC

Bowel cancer screening and prevention

Index. Note: Page numbers of article titles are in boldface type.

Colonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern

The choice of methods for Colorectal Cancer Screening; The Dutch experience

Updates in Colorectal Cancer Screening & Prevention

Microbiome as a marker for CRC screening

Dr Alasdair Patrick Gastroenterologist

Genetic testing all you need to know

Beyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University

2. Describe pros/cons of screening interventions (including colonoscopy, CT colography, fecal tests)

The molecular genetics of colorectal cancer

Colorectal Cancer Screening: Colonoscopy, Potential and Pitfalls. Disclosures: None. CRC: still a major public health problem

Prevention of Bowel Cancer: which patients do I send for colonoscopy?

FAMILIAL COLORECTAL CANCER. Lyn Schofield Manager Familial Cancer Registry

(Bowel) Cancer Screening an update. Mike Hulme-Moir Colorectal Surgeon CD NZ Bowel Screening Pilot

Colon Cancer Screening & Surveillance. Amit Patel, MD PGY-4 GI Fellow

Colorectal cancer screening

Caring for a Patient with Colorectal Cancer. Objectives. Poll question. UNC Cancer Network Presented on 10/15/18. For Educational Use Only 1

Serrated Polyps, Part 2: Their Mechanisms and Management Ryan C. Romano, DO

FECAL OCCULT BLOOD TEST (FOBT) Common Guaiac versus Immunochemical Test

Colorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital

Familial and Hereditary Colon Cancer

Colorectal Cancer. Mark Chapman. MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist

Colorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.

Familial and Hereditary Colon Cancer

General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background

M. Azzam Kayasseh,Dubai,UAE

Carol A. Burke, MD, FACG

COLON CANCER SCREENING: AN UPDATE

THE NEW ZEALAND MEDICAL JOURNAL

This is the portion of the intestine which lies between the small intestine and the outlet (Anus).

ADVANCES IN FAECAL DNA TESTING FOR COLORECTAL CANCER SCREENING: A LITERATURE REVIEW FOR PRIMARY CARE PROVIDERS

Colorectal Cancer Screening: A Clinical Update

Natural History and Epidemiology of Colorectal Cancer

The Natural History of Right-Sided Lesions

Colon Cancer Update Christie J. Hilton, DO

2012 update. Bowel Cancer. Information for people at increased risk of bowel cancer. Published by the New Zealand Guidelines Group

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

Be it Resolved that FIT is the Best Way to Screen for Colorectal Cancer DEBATE

GI Screening/Surveillance in Lynch Syndrome

Colon Screening in 2014 Offering Patients a Choice. Clark A Harrison MD The Nevada Colon Cancer Partnership

Multistep nature of cancer development. Cancer genes

Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE

Genetic Modifiers of Chemotherapy for Colorectal Cancer

Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

Cancer Screening 2009: New Tests, New Choices

Improving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)

Sessile Serrated Polyps

Biology of cancer development in the GI tract

Colorectal cancer molecular biology moves into clinical practice

Increasing Colorectal Cancer Screening in Wyoming. Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program

Hereditary Gastric Cancer

Cancer Control - the role of Surveillance. Anthony B. Miller Department of Public Health Sciences University of Toronto, Canada

General Surgery Grand Grounds

Colorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005

Give Yourself the All Clear Colorectal Cancer Prevention and Screening: What YOU Need to Know

Colonic Polyp. Najmeh Aletaha. MD

SCREENING FOR BOWEL CANCER USING FLEXIBLE SIGMOIDOSCOPY REVIEW APPRAISAL CRITERIA FOR THE UK NATIONAL SCREENING COMMITTEE

Colorectal Cancer: Preventable, Beatable, Treatable. American Cancer Society

Citation for published version (APA): Wijkerslooth de Weerdesteyn, T. R. (2013). Population screening for colorectal cancer by colonoscopy

ACG Clinical Guideline: Colorectal Cancer Screening

The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?

Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer

CRC and Endoscopy. Objectives. Background

Colon Cancer Screening. Layth Al-Jashaami, MD GI Fellow, PGY 4

Challenges for Colorectal Cancer Screening

Neoplastic Colon Polyps. Joyce Au SUNY Downstate Grand Rounds, October 18, 2012

1101 First Colonial Road, Suite 300, Virginia Beach, VA Phone (757) Fax (757)

THE NEW ZEALAND MEDICAL JOURNAL

Microsatellite instability and other molecular markers: how useful are they?

Colorectal Cancer: Screening & Surveillance

Colon Cancer Screening and Surveillance. Louis V. Antignano, M.D. Wilson Gastroenterology October 11, 2011

Colon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP

Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University WCC, Melbourne

A Trip Through the GI Tract: Common GI Diseases and Complaints. Jennifer Curtis, MD

For identification, support and follow up related to Familial Gastrointestinal Cancer conditions. South Island Cancer Nurses Network September 2013

Prof Stephen P. Halloran. Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT

Management of higher risk of colorectal cancer. Huw Thomas

Colorectal Cancer Screening. Daniel C. Chung, MD GI Unit and GI Cancer Genetics Service Massachusetts General Hospital

Universal Screening for Lynch Syndrome

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population

David P. Ryan, M.D. Clinical Director, MGH Cancer Center Chief, Hematology-Oncology, MGH

Immunotherapy in Colorectal cancer

CANCER SCREENING. Er Chaozer Department of General Medicine, Tan Tock Seng Hospital

LIST OF ABBREVIATIONS

Cancer Facts for Women

R. Piazza (MD, PhD), Dept. of Medicine and Surgery, University of Milano-Bicocca EPIGENETICS

COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University

Douglas K. Rex, MD Indiana University Hospital Indianapolis, IN

Colorectal Cancer Screening. Paul Berg MD

Transcription:

Mr Richard Perry Colorectal Surgeon Christchurch

Colorectal Cancer Richard Perry Ingo Kolossa Alison Ross Judith Collett Craig Lynch Colorectal and General Surgeon Colorectal Surgeon Gastroenterologist Gastroenterologist Colorectal and General Surgeon Intus Digestive and Colorectal Care Christchurch and Queenstown

Globocan 2008 Age Standardised Rates of colorectal cancer

CRCa Incidence per 100,000 Country cases deaths Ireland 48.7 26.4 Canada 56.8 22.4 USA 57.5 20.6 UK 60.4 28.9 Australia 62.8 24.9 NZ 69.0 31.0 Source: Globocan 2002 Database (Crude rates)

Cancer in New Zealand 2008 29,312 deaths 8,566 from cancer Source: Globocan factsheet 2008

Colorectal Cancer in NZ Every year.. FOUR people die from colorectal cancer for every: ONE who dies from an MVA and TWO who die from breast cancer 1. NZHIS. Cancer: New registrations and deaths 2004. www.nzhis.govt.nz/moh.nsf/pagesns/493 2. LTSA NZ Road toll statistics. www.ltsa.govt.nz /research/toll.htm

Objectives What s new in aetiology Genetics of Colorectal cancer Epigenetic factors Screening

Diet and Colorectal Cancer Fibre Fat Red meat Fruit Vegetables Aspirin 80mg Selenium Calcium Alcohol 13% 40% 20% but 325mg 50% 15% 100% From Marshall JR. Prevention of Colorectal Cancer. Gastroenterol Clin N Am 2008;37:73-82

The Human Microbiome 90 % of cells in human are bacteria 10 14 in gut, 10 3 different species, most in colon initially derived from mother modified by infections, antibiotics, diet symbiotic, but some produce toxic and genotoxic metabolites strict anaerobes 1000x facultative anaerobes

CRCa The role of infectious agents HPV- SCC oesophagus, cervix, anus Helicobacter Ca Stomach,? GI lymphoma Role of microflora derived β-glucuronidase by some types of dietary fibre & probiotics Fusobacterium Nucleatum implicated Constituent of oral microbiota Causes periodontitis and appendicitis

Genetic Pathways to CRCa Chromosomal Instability Mismatch Repair Deficiency CpG Island Methylation

Genetic Pathways to CRCa 1. Chromosomal Instability (CIN) 85% of Colorectal cancers =progressive in Inactivation of one methylated cytosine i.e. allele bases DNA when : predisposes repair other process already DNA to is strand intact inactivated breakage Microsatellite Stable (MSS) Results from Global DNA Hypomethylation Loss of heterozygosity (LOH) Sequential mutations: adenoma carcinoma Matsubara N. Dis Colon Rectum 2012;55(1):96-104

APC loss K-ras loss 18q loss,? DCC mutations TP53 Dysplastic aberrant crypt foci Simple adenoma Advanced adenoma Invasive carcinoma

Genetic Pathways to CRCa 2. Microsatellite Instability (MIS) Inherited (Lynch Syndrome) or sporadic (MSI-H) Accumulation of mutations in Microsatellites Due to MisMatch Repair (MMR) gene dysfunction MLH1, MSH2, PMS1, PMS2, MSH6 Microsatellites: short sequences of repeating units of 1-6 base pairs E.g. silencing of MLH1 due to promoter methylation

Genetic Pathways to CRCa 3. Epigenetic CpG Island Methylation (CIMP) 10-15% of sporadic CRCa serrated adenomas / hyperplastic polyps BRAF oncogene mutation CIMP +ve tumours: older women right colon high grade, mucinous

Treatment implications of Genetics MSI tumours not 5-FU responsive MMR failure impairs pyrimidine effect of 5-FU...but ARE Irinotecan & Oxaliplatin responsive KRAS tumours not EGFR Mab responsive Future therapeutic possibilities Pathway deregulation Wnt, EGFR, TGR-β?MicroRNA (mir) role

Epigenetic events in CRCa Heritable changes in gene expression DNA methylation Histone modification Chromatin remodelling microrna CpG islands densely methylated in CRCa silences transcription microrna switched on and off by CpG methylation Hundreds of epigenetic effects documented

Epigenetics and dietary prevention of CRCa Curcumin (turmeric) Inhibits histone acetyl transferase Inhibits mi-rna-21 expression proliferation Butyrate Inhibits histone deacetylase apoptosis Epigallocatechin gallate (EGCG) in green tea Demethylates methylated DNA reactivates silenced tumour suppressor genes Garlic, Broccoli, Selenium, Folate.etc

microrna 1247 acts as tumour suppressor in CIMP type CRCa gene mrna protein cell proliferation microrna causes mrna to be degraded microrna 1247 mrna cell proliferation

Adenoma Carcinoma sequence an opportunity for prevention Chen s model: 30% CRCa de novo, 70% from polyps Risk of transformation to carcinoma Adenomas 6-10mm = 2.17x (compared to <5mm) Adenomas >10mm = 4.25x Mean time to transition Adenomas 6-10mm to >10mm = 7.75yrs Adenomas >10mm to Cancer = 5.27yrs Chen C-D et al. BrJCancer 2003;88(12):1866-73

Early detection and Prevention Faecal Occult Blood testing Guaiac (gfobt) Faecal Immunochemical Testing (ifobt) Flexible Sigmoidoscopy CT Colonography Colonoscopy

American Cancer Society Recommendations since 2001 Test Interval from age 50 Comment FOBT Yearly +ve tests Colonoscopy Flexible Sigmoidoscopy 5 yearly +ve tests Colonoscopy Colonoscopy 10 yearly

Why Faecal Occult Blood Testing? 4 prospective randomised trials 1 Funen, Nottingham, Minnesota, Goteborg 16% reduction in mortality from CRCa after 10-18 years of annual gfobt Possibly 25% reduction in active participants Participation in FOBT better: 34% vs 25% for Colonoscopic Screening programs 2 There have been no PRTs of colonoscopic screening 1. Hewitson P et al Am J Gastro 2008; 103(6):1541-9 Cochrane Review 2. Quintero E et al NEJM 2012;366(8):697-706

Which Faecal Occult Blood Test? ifobt (FIT) better than gfobt (guaiac) ifobt vs gfobt 1 Sensitivity Specificity PPV Carcinoma 70% vs 79% 94% vs 87% 5.0 vs 2.5 Ca or Polyp>1cm 67% vs 69% 95% vs 87% 20.5 vs 9.2 NZ Waitemata pilot using ifobt in 50-74yo pop n Questions cut-off values: 50ng Hb/ml 200ng Hb/ml Age to screen: 49% of CRCa patients <50 or >75 2 1. Allison JE et al NEJM 1996;334(3):155-9 2. Shellnut JK et al DisColonRectum 2012;53:5-8

Optimising compliance with Screening Compliance typically < 50%..as low as 20% GP critical to success Education / Awareness raising Working through through social & cultural barriers 1 Discussing too many options causes confusion Confusion reduces compliance 2 1. Reeder AI NZMJ 2011;124(1331):1-11 2. Jones RM et al Cancer Epidemiology, Biomarkers & Prevention 2010;19(11):2821-5

Concerns about FOBT screening PRCTs not powered to show total mortality 81-95% false +ves 1 Verification bias may overestimate sensitivity False negative rates not ascertained Sensitivity 0.36 (0.25-0.47) when -ve FOBTs verified vs 0.70 (0.60-0.80) if not 2 Higher sensitivity for Left vs Right sided CRCa 3 Only 25% of CRCas detected by screening Remainder interval Cancers or in non-compliers 1. Ekelund et al Int J Colorectal Dis 2010 2. Rosman AS & Korsten MA JGIM 2010 (Meta-analysis of verification bias) 3. Haug et al Expert RevMolDiagn 2011 (Meta-analysis)

Colonoscopy following +ve FOBT Expect 5-8% +ve ifobts ~90% compliance with colonoscopy? Cancer detection rate 4-6% Adenoma detection rate 40-60% Perforation rate <1% Bleeding rate <1% Gupta S. Colorectal Disease 2012;14(2):166-73 (St Marks Bowel Cancer Screening Centre) Parente F et al Br J Surg 2009;96(5):533-540 (Lecco, Italy)

A +ve ifobt rate of 8% would lead to same number of colonoscopies as one-off colonoscopy screening at 60 NZ Colorectal Cancer Screening Advisory Group Report 2006

CRCa Colonoscopy yield vs FOBT Similar per invited person (0.1%) Greater per screened person (0.5% vs 0.3% ) Advanced adenomas 1.9% vs 0.9% p<0.001 Small adenomas 4.2% vs 0.4% p<0.001 and. Quintero E et al NEJM 2012;366(8):697-706 (Spanish PRT; Colonoscopy vs ifobt screening due 2021) Bretthauer M et al NEJM 2012;366(8):759-60

Patients who die from CRCa are less likely to have had a Colonoscopy Ontario case-controlled study 10,292 CRCa patients matched 51,460 controls Case patients less likely to have had colonoscopy (OR 0.69: 0.63-0.74, p<0.001) Complete colonoscopy strongly associated with fewer deaths from Left sided CRCa (OR 0.33: 0.28-0.39) Baxter NN et al Ann Int Med 2009

Flexible Sigmoidoscopy prevents CRCa Prospective Multicentre Randomised Trial - UK Flex Sig (57,237 patients) vs Control (113,195 patients) Single examination age 55-64 Outcome: incidence & death from CRCa median fu 11.2yrs Incidence distal CRCa 50%, All CRCa 23% Mortality from CRCa 43% Atkin WS, Lancet 2010

Flexible Sigmoidoscopy prevents CRCa Prospective Multicentre Randomised Trial - Italy Flex Sig (17,136 patients) vs Control (17,136 patients) Single examination age 55-64 Outcome: incidence & death from CRCa median fu 10.5yrs Incidence CRCa 18% (intention to treat analysis) Mortality from CRCa 22% Atkin WS, Lancet 2010

Colonoscopy prevents more colorectal cancer deaths 9112 patients without personal or FHx CRCa 2602 had adenomas removed 12 died CRCa median fu 16yrs 25.4 expected deaths in general population Suggests 53% reduction in mortality vs 18% from FOBT screening Zauber AG et al, NEJM 2012;366(8):687-96 (National Polyp Study)

An appealing concept would be to use colonoscopy as a triage screening test, offering it once for everybody at 60 years of age and using the results to classify persons as having a low risk of colorectal cancer (no adenomas detected) or a high risk (adenomas detected, particularly advanced ones), with strict surveillance for the latter group but no further screening for the former. Dr Michael Bretthauer, Riks Hospital Oslo, in Editorial, NEJM 2012;366(8):759-60

Improving Colonoscopy Acceptability Preparation Low volume, palatable, few side-effects Fluid & Electrolyte support Social normalisation Facilitative, supportive communications Non-clinical examination environment Technical Gentle technique; anticipate difficulties Minimal Sedation, Patient engagement

Measuring the quality of Colonoscopy differences between endoscopists polyp detection rates were significant p<0.001 1 MNP: Mean number of polyps 2 Ileal intubation rate (>95%) Patient satisfaction vs Sedation Inspection / withdrawal time (>6 mins) Complication rates Perforation <0.1% of biopsies, Bleeding <0.2% Post-colonoscopy pain 1 Chen SC. Am J Gastroenterol 2007;102,856-861 2 Denis B et al. Gastrointestinal Endoscopy 2011; 74(6):1325-36

Conclusion Pick your pedigree Control the epigenetic phenomena diet, probiotics,?viral mediated Mi-RNA transfection.etc watch this space Remove polyps urgent need to expand resources for community colonoscopy